Radiation-induced senescence: therapeutic opportunities

Radiation Oncology

Review

Marcia N. Gordon¹  Stephen L. Brown²  Jae Ho Kim² 

[1] Department of Translational Neuroscience, Michigan State University, 49503, Grand Rapids, MI, USA;Radiobiology Research Laboratories, Department of Radiation Oncology, Henry Ford Health, 2799 West Grand Boulevard, 48202, Detroit, MI, USA;

关键词: Radiation injuries;    Cellular senescence;    Senescence-associated secretory phenotype;    Senotherapeutics;   

DOI  :  10.1186/s13014-022-02184-2

 received in 2022-04-05, accepted in 2022-12-19,  发布年份 2022

来源: Springer

【 摘 要 】

The limitation of cancer radiotherapy does not derive from an inability to ablate tumor, but rather to do so without excessively damaging critical tissues and organs and adversely affecting patient’s quality of life. Although cellular senescence is a normal consequence of aging, there is increasing evidence showing that the radiation-induced senescence in both tumor and adjacent normal tissues contributes to tumor recurrence, metastasis, and resistance to therapy, while chronic senescent cells in the normal tissue and organ are a source of many late damaging effects. In this review, we discuss how to identify cellular senescence using various bio-markers and the role of the so-called senescence-associated secretory phenotype characteristics on the pathogenesis of the radiation-induced late effects. We also discuss therapeutic options to eliminate cellular senescence using either senolytics and/or senostatics. Finally, a discussion of cellular reprogramming is presented, another promising avenue to improve the therapeutic gain of radiotherapy.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq387.gif

41116_2022_35_Article_IEq366.gif

41116_2022_35_Article_IEq353.gif